Distinguished in Thymic Epithelial Tumor

Dr. Naiyer A. Rizvi

Oncology

1275 York Ave,

New York, NY

Clinical Trials:Currently Recruiting for 1 Trial

Distinguished in Thymic Epithelial Tumor

1275 York Ave,

New York, NY

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Naiyer Rizvi is an Oncologist in New York, New York. Dr. Rizvi is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare

Locations

1275 York Ave, New York, NY 10021

Call: 646-227-3813

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Recruiting

Publish Date: July 03, 2024

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: December 17, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Other, Procedure

Study Phase: Phase 3

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers

Enrollment Status: Completed

Publish Date: August 11, 2025

Intervention Type: Biological

Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody

Study Phase: Phase 1

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade

Enrollment Status: Active_not_recruiting

Publish Date: May 12, 2025

Intervention Type: Drug

Study Phase: Phase 2

A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: December 27, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: August 28, 2024

Intervention Type: Drug

Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab

Study Phase: Phase 1/Phase 2

A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Completed

Publish Date: December 12, 2023

Intervention Type: Drug

Study Drugs: MPDL3280A, Carboplatin, Nab-Paclitaxel

Study Phase: Phase 2

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.

Enrollment Status: Terminated

Publish Date: July 24, 2023

Intervention Type: Drug

Study Drugs: Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed

Study Phase: Phase 2

A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)

Enrollment Status: Completed

Publish Date: June 09, 2023

Intervention Type: Biological, Other

Study Drugs: Durvalumab, Tremelimumab

Study Phase: Phase 2

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Enrollment Status: Completed

Publish Date: June 01, 2023

Intervention Type: Biological, Drug, Other

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Terminated

Publish Date: September 21, 2022

Intervention Type: Drug, Dietary supplement, Biological

Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone

Study Phase: Phase 2

A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: February 10, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Enrollment Status: Completed

Publish Date: February 08, 2022

Intervention Type: Biological

Study Phase: Phase 1

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Enrollment Status: Completed

Publish Date: August 30, 2021

Intervention Type: Drug

Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab

Study Phase: Phase 1

A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Enrollment Status: Completed

Publish Date: June 23, 2021

Intervention Type: Other, Drug

Study Drug: Talazoparib

Study Phase: Phase 2

A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Enrollment Status: Completed

Publish Date: May 27, 2021

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Palbociclib

Study Phase: Phase 2/Phase 3

A Phase I Study Evaluating the Safety and Efficacy of SGI-110 Followed by Combined Durvalumab Plus Tremelimumab in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Enrollment Status: Completed

Publish Date: December 10, 2018

Intervention Type: Drug

Study Phase: Phase 1

View 20 Less Clinical Trials

116 Total Publications

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 01, 2025

View All 116 Publications

Similar Doctors

Elite in Thymic Epithelial Tumor

Dr. Gregory J. Riely

Oncology

Elite in Thymic Epithelial Tumor

Dr. Gregory J. Riely

Oncology

Memorial Solid Tumor Group

530 E 74th St,

New York, NY

(0.3 miles away)

212-639-2000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Gregory Riely is an Oncologist in New York, New York. Dr. Riely is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Thymic Epithelial Tumor, Tissue Biopsy, and Liver Embolization. Dr. Riely is currently accepting new patients.

Elite in Thymic Epithelial Tumor

Dr. Giuseppe Giaccone

Hematology Oncology | Oncology | Hematology

Elite in Thymic Epithelial Tumor

Dr. Giuseppe Giaccone

Hematology Oncology | Oncology | Hematology

New York Queens Medicine And Surgery, P.C.

5634 Main St, Fl 1,

Flushing, NY

(6.9 miles away)

718-670-2468

Languages Spoken:

English

Giuseppe Giaccone is a Hematologist Oncology specialist and an Oncologist in Flushing, New York. Dr. Giaccone is rated as an Elite provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Thymic Epithelial Tumor, Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

Advanced in Thymic Epithelial Tumor

Dr. Afsheen N. Iqbal

Oncology | Hematology

Advanced in Thymic Epithelial Tumor

Dr. Afsheen N. Iqbal

Oncology | Hematology

Memorial Solid Tumor Group

1275 York Ave,

New York, NY

(0.1 miles away)

212-639-2000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Afsheen Iqbal is an Oncologist and a Hematologist in New York, New York. Dr. Iqbal is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

VIEW MORE THYMIC EPITHELIAL TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rizvi's expertise for a condition

ConditionClose